Advanced Systemic Mastocytosis research hub

A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies

This study is looking at a new drug, BLU-263, for a rare blood cancer called Advanced Systemic Mastocytosis. It will be tested alone and with another drug, azacitidine, to see how safe it is and how well it works.